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E-mail addresses: molecule85@pusan.ac.kr, jhcheoThe caudal-associated homeobox transcription factor, CDX1, performs critical functions in intestinal
cell proliferation, differentiation, and neoplasia. In this study, we have identiﬁed the molecular
mechanism underlying the CDX1-mediated regulation of intestinal cell differentiation. CDX1
enhanced the expression of PPARc gene, a master transcriptional regulator of intestinal differenti-
ation, at the transcriptional level, via functional interaction with CCAAT/enhancer-binding protein
alpha (C/EBPa). Butyrate, an intestinal differentiation inducer, increased the protein interaction of
CDX1 and C/EBPa, thereby resulting in a signiﬁcant increase in PPARc expression. These results
show that the regulation of target gene expression for intestinal determination is dependent on a
transcriptional cascade of CDX1, C/EBPa, and PPARc.
Structured summary:
MINT-6800304: CDX1 (uniprotkb:P47902) physically interacts (MI:0218) with CEBPalpha (uni-
protkb:P49715) by pull down (MI:0096)
MINT-6800330: CDX1 (uniprotkb:P47902) physically interacts (MI:0218) with CEBPalpha (uni-
protkb:P49715) by two hybrid (MI:0018)
MINT-6800315: CEBPalpha (uniprotkb:P49715) physically interacts (MI:0218) with CDX1 (uni-
protkb:P47902) by anti bait co-immunoprecipitation (MI:0006)
 2008 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction creases the crypt-to-villus gradient and may also prove relevantShort-chain fatty acids (SCFAs) represent a natural component
within the gut lumen as a byproduct of ﬁber fermentation by the
intestinal microﬂora, and thus perform a function in the homeosta-
sis of colonic mucosa, by exploiting the colonic cell maturation
pathways [1,2]. Among all SCFAs, butyrate has a profound inﬂu-
ence on colonic epithelial cells, and is considered to assist in the
maintenance of colonic homeostasis. Butyrate treatment in colonic
HT29 cells exerts several cellular effects, including cell cycle arrest,
the induction of p21, and apoptosis, which may contribute to the
differentiated pattern seen in intestinal epithelial cells, and results
in enterocyte-like differentiation during the differentiation pro-
cess, as shown by the induction of the brush-border enzymes,
intestinal alkaline phosphatase (ALP) and sucrase-isomaltase [3].
Peroxisome proliferator-activated receptor gamma (PPARc) is
expressed at signiﬁcant level of the large intestine, where it in-chemical Societies. Published by E
activated receptor gamma;
FA, short-chain fatty acids;
ng2@lycos.co.kr (J. Cheong).to normal or pathological functions in intestinal tumors and colon
cancer [4–8]. The CDX gene family, an intestine-speciﬁc transcrip-
tion factor, is a member of the caudal-related homeobox gene fam-
ilies, which are critical regulatory proteins for developmental,
proliferation and differentiation processes [9,10]. Several studies
have established that CDX1 and CDX2 are restricted to the colonic
epithelium and are expressed throughout the small and large intes-
tine, and that they regulate the intestinal epithelial cell phenotype
via the coordination of proliferation, differentiation, and apoptotic
processes [11,12]. CDX1 and CDX2 are involved in the regulation
of speciﬁc intestinal promoters, including intestinal ALP, sucrase-
isomaltase, intestinal phospholipase A/lysophospholipase (IPAL)
and p21 [12–14]. These genes are critical to the process of intestinal
homeostasis, as they regulate the balance between proliferation
and differentiation in intestinal epithelial cells.
However, the molecular mechanisms underlying CDX-mediated
gene regulation during intestinal differentiation remain to be
clearly elucidated. In this study, we show, for the ﬁrst time, that
CDX1 is required for the induction of PPARc expression and
interacts with another differentiation transcription factor, CCAAT/
enhancer-binding protein alpha (C/EBPa), and butyrate increaseslsevier B.V. All rights reserved.
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gene expression.2. Materials and methods
2.1. Cell culture
HT29 cells maintained in Dulbecco’s modiﬁed Eagle medium
(DMEM) with 10% heat-inactivated FBS and 1% (v/v) penicillin–
streptomycin (PS) (GIBCO BRL) at 37 C in a humid atmosphere
of 5% CO2. To induce intestinal differentiation, HT29 cells were
seeded and growth in the presence of butyrate for 48 h. HT29-
CDX1 stable cell were maintained in DMEM supplemented with
10% FBS containing antibiotics G418.
2.2. Transfection and luciferase reporter assay
Cells were seeded in a 24-well culture plate and transfected
with reporter vector and b-galactosidase expression plasmid for
normalization, along with each indicated expression plasmids
using the SuperFect according to the manufacturer’s instructions.
After 48 h of transfection, the cells were lysed in the cell culture ly-
sis buffer (Promega). Luciferase activity was determined using an
analytical luminescence luminometer according to the manufac-
turer’s instructions. Luciferase activity was normalized for trans-
fection efﬁciency using the corresponding b-galactosidase
activity. Data shown are means ± S.D. of three independent exper-
iments performed in duplicate.
The construction of siRNA targeted to CDX1 and PPARcwas car-
ried out according to the instruction manual provided by the man-
ufacturer (Bioneer, Korea). For the construction of CDX1 siRNA (the
sense; 50-ACAAGGAUUCGCCCGUGUA-30; the antisense; 50-UA-
CACGGGCGAAUCCUUGU-30) and PPARc siRNA (the sense;
50-GAGAAGACUCAGUACA-30; the antisense; 50-UGUAGAGCUGA-
GUCUUCUC-30) oligonucleotides were synthesized. The transfec-
tion of HT29 cells were carried out by HiPerFect according to the
instruction manual provided by the manufacturer (QIAGEN).
2.3. Site-directed mutagenesis
A critical potential CDX1 binding sequence between 76 and
16 containing PPARc2 promoter was generated by site-directed
mutagenesis. Primers containing a four-point mutation in 76/
+68 PPARc2 promoter (sense: 50-GGTGTCTTGACCCGCTAGCATA-
TTCAT-30, antisense: 50-ATGAATATGCTAGCGGGTCAAGACACC-30)
were used for PCR ampliﬁcation, and PCR products were ligated
into pGL3-basic luciferase reporter.
2.4. Mammalian two-hybrid assay
Cells were seeded with growth medium supplemented with
10% fetal bovine serum and 1% (v/v) penicillin–streptomycin (PS)
and co-transfected with expression vectors encoding Gal4-DNA-
binding domain fusions (pCMX/Gal4N/CDX1) and VP16-activation
domain fusions (pCMX/VP16/C/EBPa) as well as the previously
described Gal4-tk-luc reporter plasmid. After 48 h, cells were
harvested and the luciferase activity was normalized to the
b-galactosidase internal standard. All the results represent the
average of at least three independent experiments.
2.5. Alkaline phosphatase (ALP) activity assay
As a measure of cell differentiation, ALP activity from cell lysate
was determined by commercially available kit from Sigma. Each
cell line was seeded in 24-well plate and were incubated for 48 hin the absence or present 2 mM butyrate (Sigma Chemical Co., St.
Louis, MO). Alkaline phosphatase substrate was added to the cell
lysis extract and then incubation at 37 C for 1 h. Enzyme activ-
ity was measured using microplate reader at a wave length of
405 nm.
2.6. RNA preparation and RT-PCR
Total RNA from HT29 cells was prepared using Trizol reagent
(Invitrogen) according to the manufacturer’s recommendation.
The cDNA was synthesized from total RNA with AMV Reverse
Transcriptase (Promega) using a random hexamer (Bioneer) at
42 C for 1 h. The PCR primers for CDX1 gene ampliﬁcation were:
50-GCAGTATTCTCCAGCTACTCTCA-30 (sense), 50-CATTGGAGA-
GGAGGTGGCCAGG-30 (antisense), PPARc gene ampliﬁcation: 50-
GAAATGACCATGGTTGAC-30 (sense), 50-GAAATGACCATGGTTGAC-
30 (antisense), p21 gene ampliﬁcation: 50- GCTGAGCCGCGACTGT-
GATGCGCTAAT-30 (sense), 50-GAGAAGATCAGCCGCGTTTGGAG-
TGG-30 (antisense), MUC2 gene ampliﬁcation: 50-CCATTCTCAAC-
GACAACCCCTACCCC-30 (sense), 50-TCCAATGGGAACATCAGGATA-
CATGGTGGC-30 (antisense), villin gene ampliﬁcation: 50-
ACACAGGTGGAGGTGCAGAAT0 (sense), 50-TCGAACTTCACCTGTTC-
CACTTT-30 (antisense) and b-actin gene ampliﬁcation were: 50-
GACTACCTCATGAAGATC-30 (sense), 50-GATCCACATCTGCTGGAA-30
(antisense). The cDNAs were ampliﬁed by PCR under the following
conditions: 28 cycles of denaturation at 95 C for 30 s, annealing at
55 C for 30 s, and extension at 72 C for 30 s in a thermal cycle.
The PCR products were examined by electrophoresis on 1.2% aga-
rose gel.
2.7. Western blot analysis
Cells were suspended in a lysis buffer (150 mM NaCl, 1.0% NP-
40, 1 mM EDTA, 50 mM Tris, pH 7.5) containing protease inhibi-
tors, and quickly sonicated on ice. Protein concentrations were
measured using a commercial Protein Assay (Bio-Rad). Whole cell
lysates was subjected to 10% SDS–PAGE and transferred to a PVDF
membrane (Millipore) by semidry electroblotting. The membranes
were then incubated for 2 h at room temperature with anti-CDX
(AB4122, Chemicon), anti-C/EBPa (sc-61, Santa Cruz), anti-PPARc
(sc-7196, Santa Cruz), anti-Villin (610358, BD biosciences), anti-
p21 (sc-6246, Santa Cruz), anti-HA (Roche), anti-GST (sc-138, Santa
Cruz) or anti-actin (A2066, Sigma) in TBST supplemented with 1%
non-fat dry milk. After washing three times with cold TBST, the
bands were detected using an enhanced chemiluminescence sys-
tem (Amersham).
2.8. Co-immunoprecipitation assay
Cell lysates were incubated with 1 lg of anti-C/EBPa antibody
at 4 C for 3 h with gentle agitation. Immune complexes were col-
lected on protein A-Sepharose beads (Invitrogen). After washing
three times with extensively with lysis buffer, the precipitates
were boiled with an equal volume of 2 Laemmli sample buffer
and separated by SDS–PAGE, and subjected to Western blot
analysis.
2.9. In vivo GST pull-down assay
The GST/CDX1 and C/BEPa expression plasmids (pcDNA3/GST/
CDX1 and pCMX1/C/EBPa, respectively) were co-transfected into
HT29 cells. Forty-eight hours after transfection, the cells were har-
vested and lysed to yield the cell extract. GST/CDX1 was puriﬁed
from the cell extract with glutathione-Sepharose beads (Amer-
sham) were incubation at 4 C for overnight with gentle agitatio-
and. After washing three times with extensively with lysis buffer,
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Fig. 1. The effects of CDX1 and CDX2 on the transcriptional expression of PPARc. (A, B) Protein expression patterns of CDX, PPARc, and C/EBPa in butyrate-induced intestinal
differentiation dependent on concentrations (A) and time periods (B). (C, D) The transcriptional activities of CDX1 (C) and CDX2 (D) on PPARc2 promoter. Upper panel shows
the luciferase activities and lower panel indicates mRNA expression through RT-PCR.
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monoclonal antibody to C/EBPa.
3. Results and discussion
3.1. Butyrate treatment in colon HT29 cells increases expression of
CDX1 and PPARc proteins
Human colon adenocarcinoma HT29 cells provide a unique and
well-characterized model for the study of intestinal epithelial dif-
ferentiation. These cells were modulated to express distinct
enterocyte differentiation pathways, and formed brush-borders
on apical surfaces under appropriate culture conditions, or as the
result of treatment with a variety of agents [15,16]. In order to
investigate the function of butyrate in intestinal cell differentiation
and to determine the appropriate experimental conditions, HT29
cells were induced to differentiate via butyrate treatment with
increasing concentrations and time courses. CDX1 and PPARc pro-
tein expression were stimulated by up to 5 mM butyrate, but by
CDX2 up to 2 mM as compared with the control cells (Fig. 1A). It
has been well established that three isoforms of C/EBP are ex-
pressed prior to villus formation [17]. The expression of C/EBPa
protein was gradually induced by butyrate treatment at increasing
concentrations and time courses, and we observed maximal stim-
ulation at 2 mM butyrate. The time course study indicated that
CDX1 induction was detected beginning at 24 h, and CDX2 andPPARc expression were slightly increased until 48 h (Fig. 1B). Lev-
els of villin and p21 protein, as intestinal differentiation markers,
also were increased signiﬁcantly at 2 mM of butyrate, and the
maximal effects were observed at 48 h.
3.2. CDX1 increases PPARc2 promoter activity
CDX1 and CDX2 have been shown to regulate the expression
of intestine-speciﬁc gene promoters, including intestinal ALP, su-
crase-isomaltase, intestinal phospholipase A/lysophospholipase
(IPAL) and p21, via binding to an AT-rich consensus sequence
(A/CTTATA/G) in either direct or reverse orientation [11–13].
From the database analysis of the promoter region for known
consensus sequences in the PPARc2 promoter, several putative
CDX response elements were detected in the PPARc2 promoter
[18]. In order to determine whether CDX1 and CDX2 transcription
factors regulate PPARc gene expression, HT29 cells were transfec-
ted with the PPARc2-luciferase reporter plasmid along with
expression vectors encoding for CDX1 and CDX2, respectively.
CDX1 expression induced a gradual increase in the promoter
activity of PPARc2 in a dose-dependent manner (Fig. 1C, upper
panel). Consistent with the results of the reporter assay, the levels
of PPARc mRNA were increased signiﬁcantly in the presence of
CDX1 overexpression (Fig. 1C, lower panel). In contrast, CDX2
had no effect on PPARc2 promoter activity or mRNA expression
(Fig. 1D).
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We subsequently identiﬁed the CDX1 responsive region in the
PPARc2 promoter. It was determined that ﬁve tentative CDX1
binding sites exist within the PPARc2 promoter. A series of sequen-
tially deleted constructs of the PPARc2 promoter were prepared
and subjected to reporter assays with the cotransfection of the
CDX1 expression plasmid into HT29 cells. The various deleted con-
structs of the PPARc2 promoter are described in Fig. 2A. CDX1
expression in HT29 cells resulted in a four- and ﬁve-fold activation
of the deletion constructs of the PPARc2 promoter, with the excep-
tion of the p 16/+68 promoter construct. Promoter activity, based
on luciferase expression, was dramatically reduced between the p
16/+68 and p 76/+68 promoter constructs, which suggests that
a positive CDX1 response element site may exist between 76 and
16 of the PPARc2 promoter (Fig. 2B). In order to determine
whether the PPARc2 promoter region between 76 and 16 har-
bors a speciﬁc regulatory binding site for CDX1, an internal substi-
tution mutant in the p 76 and +68 of the PPARc2 promoter
construct was prepared, in which the putative CDX1 response ele-
ment CTTATTAG was changed to CCCGCTAG. As shown in Fig. 2C,
this site-directed mutation resulted in a signiﬁcant loss of lucifer-
ase activity as compared with the wild type of the p 76/+68
PPARc2 promoter.
Next, in order to further determine the role of butyrate on
CDX1-mediated PPARc transactivation, HT29 cells were transfec-A
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of CDX1. After transfection, luciferase activity, mRNA and protein expression were meated with the PPARc2-luciferase reporter plasmid along with an
expression vector encoding for CDX1 or an empty vector as a con-
trol in the absence or presence of butyrate. The results shown in
Fig. 2D illustrate that CDX1 and butyrate cooperatively induce an
increase in the activity of the PPARc promoter. In addition, the
knockdown of CDX1 using a small interfering RNA (siRNA) gave
rise to a reduction in the transcriptional activity of the PPARc2 pro-
moter in the presence of butyrate. In an effort to verify the level of
PPARc expression along with siRNA directed against CDX1, RT-PCR
and Western blotting was conducted. The knockdown of CDX1 re-
sulted in the reduction of PPARc and villin mRNA and protein
expression.
3.4. CDX1 induces PPARc expression in butyrate-induced intestinal
differentiation
In order to evaluate the effect of CDX1 on the expression of the
PPARc gene, HT29 cells were transiently transfected with the CDX1
expression vector or with empty vector as a control. As shown in
Fig. 3A, CDX1 overexpression stimulated PPARc protein levels in
the transiently transfected HT29 cells. Villin and p21 protein levels,
used as intestinal differentiation markers, were also increased as
compared with the empty vector-transfected cells. In order to fur-
ther conﬁrm the PPARc expression as the result of CDX1 overex-
pression in intestinal epithelial cells, CDX1 was stably transfected
into HT29 cells. HT29 cells stably expressing the CDX1 proteinLuc
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Fig. 3. Requirement of CDX1 for butyrate-induced PPARc expression. (A, B) Increasing effect of CDX1 on butyrate-induced PPARc expression. After a transient transfection (A)
and establishment of stable expressing cells of CDX1 (B), the cell extracts were applied to Western blot analysis. (C) Increased ALP activity in HT29/CDX1 stable cells. (D)
Dependence of PPARc on CDX1-directed alkaline phosphatase expression.
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(Fig. 3B). In order to further determine whether CDX1-mediated
PPARc gene expression is enhanced by butyrate, the same experi-
mental strategy was applied, administering butyrate treatment to
the transfected cells. As shown in Fig. 3A and B, CDX1-expressing
cells signiﬁcantly increased levels of PPARc, villin, and p21 protein
in the presence of butyrate in the transiently and stably transfected
HT29 cells, respectively. To conﬁrm the results mentioned above,
we examined ALP activity, which has been well characterized as
a marker for absorptive cell differentiation [19]. As shown in
Fig. 3C, we noted increased ALP activity in CDX1 stable cells
(HT29/CDX1 cells) as compared with HT29 and empty vector sta-
ble cells (HT29/Mock cells). 48 h of butyrate treatment in HT29/
CDX1 stable cells resulted in a synergistic increase in ALP activity
as compared with the untreated cells.
To further evaluate the PPARc function in CDX1-mediated
intestinal differentiation, HT29, HT29/Mock stable, and HT29/
CDX1 stable cells were transfected either with siRNA targeted
against PPARc or with a scrambled oligonucleotide in the presence
or absence of butyrate treatment. As shown in Fig. 3D, ALP activity
was induced in HT29/CDX1 stable cells in a butyrate-dependent
manner as compared with the HT29 and HT29/Mock stable cells,
whereas ALP activity was reduced in cells expressing siRNA against
PPARc.
3.5. Cooperation of CDX1 and C/EBPa increases PPARc2 promoter
activity and protein expression
The results of several studies have shown that C/EBPa regulates
PPARc transcription, and is also associated with the regulation ofintestinal differentiation [17,18]. In order to determine whether
the CDX1-dependent transactivation of the PPARc promoter is in-
creased by C/EBPa in the intestinal differentiation process, we co-
transfected cells with the PPARc2 luciferase reporter plasmid,
along with expression vectors encoding for CDX1 and C/EBPa.
The co-expression of the CDX1 and C/EBPa proteins resulted in a
cooperative transcription activity of the PPARc promoter (Fig. 4A,
left). The co-expression of CDX1 and C/EBPa gave rise to increased
expression of the villin protein as well as PPARc (Fig. 4A, right).
Considering the cooperative transcription activity of C/EBPa
and CDX1 on the PPARc2 promoter, we attempted to determine
whether CDX1 associates with C/EBPa via in vivo GST pull-down
assays. The expression plasmids of GST-CDX1 and C/EBPa were
co-transfected into HT29 cells. The GST-CDX1 was puriﬁed from
the cell extract with glutathione-Sepharose beads, and GST-
CDX1-bound C/EBPa was detected via immunoblotting using C/
EBPa antibody. As shown in Fig. 4B, GST-CDX1 bound to C/EBPa,
whereas GST alone did not. We also veriﬁed the physical interac-
tion of these proteins via co-immunoprecipitation assays with
HT29 cells co-transfected with HA-CDX1 and C/EBPa constructs,
followed by immunoblotting analysis. HA-CDX1 was detected as
a co-precipitant in a C/EBPa-bound complex (Fig. 4C). With regard
to the possibility that butyrate treatment had enhanced the associ-
ation of CDX1 and C/EBPa in the transactivation results, it was sug-
gested that butyrate might exert an inﬂuence on the association
between CDX1 and C/EBPa in vivo. Butyrate treatment caused a
strong interaction between CDX1 and C/EBPa (Fig. 4C). These re-
sults indicate that CDX1 can induce PPARc transactivation via di-
rect protein–protein interaction with C/EBPa. The results of a
mammalian two-hybrid assay further showed that the physical
40
30
20
10
0Re
la
tiv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
(F
old
)
CDX1
C/EBPα
+
-
-
+
+
+
-
-
PPARγ2-Luc
A
anti-HA
anti-C/EBP
anti-PPARγ
anti-Villin
anti-Actin
HA/CDX1
C/EBPα
α
-
-
+
-
-
+
+
+
B
60
50
40
30
20
10
0R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
(F
old
)
Gal4tk -Luc
Gal4N
VP16N
Gal4N/CDX1
VP16N/C/EBPα
-
-
-
-
+
-
-
-
-
-
+
-
-
-
-
+
-
+
-
-
-
-
+
+
Control
Butyrate (2 mM)
D
CDX1
C/EBPα
PPARγ
p21
MUC2
Villin
β-actin
C/EBPα
Butyrate (2mM)
-
-
+
-
+
+
HT29-CDX1 stable cells
E 800
600
400
200
0
A
LP
 a
ct
iv
ity
 (m
U/
mg
)
HT29 HT29/Mock HT29/CDX1
Mock
Mock (2mM, Butyrate)
C/EBPα
C/EBPα (2mM, Butyrate)
C
GST
GST/CDX1
C/EBPα
+
-
+
-
+
+
WB;  anti-C/EBPα
WB;  anti-GST
5%
Input
Pull
down
GST/CDX1
GST
+
-
+
-
+
+
HA/CDX1
C/EBPα
Butyrate (2 mM)
IP ; anti-C/EBPα
IB ; anti- HA
-
+
-
+
+
-
anti-C/EBPα
anti- HA
+
+
+
5% In
pu
t
Fig. 4. C/EBPa increases CDX1-dependent PPARc expression. (A) Cooperative transactivation of C/EBPa and CDX1 on PPARc expression. After transfection, luciferase activity
and protein expression were measured. (B) In vivo GST pull-down assay for interaction of CDX1 and C/EBPa. (C) Co-immunoprecipitation assay for interaction of CDX1 and C/
EBPa. After transfection, the cell lysates were subjected to immunoprecipitation with anti-C/EBPa antibody. (D) Mammalian two-hybrid assay for interaction of CDX1 and C/
EBPa. HT29 cells were transiently transfected with reporter plasmid alone, or with reporter plasmid plus the mammalian expression plasmids encoding for Gal4N-CDX1 and
VP16N-C/EBPa, as indicated. (E) Increased alkaline phosphatase assay by C/EBPa overexpression in HT29 cells expressing CDX1.
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by treatment with 2 mM butyrate (Fig 4D).
In order to determine whether CDX1 and C/EBPa inﬂuence the
differentiation of intestinal cells, we attempted to determine
whether the overexpression of C/EBPa in HT29, HT29/Mock stable,
and HT29/CDX1 stable cells would increase ALP activity. As ex-
pected, C/EBPa alone results in a slight induction of ALP activity
in HT29 and HT29/Mock stable cells. HT29/CDX1 stable cells with
C/EBPa overexpression induced more ALP activity than was ob-
served in HT29 and HT29/Mock expressing cells (Fig. 4E, left). In
addition, butyrate treatment further increased ALP activities. Con-
sistent with the results of the ALP assay, the levels of PPARc, p21,
MUC2 and villin mRNA were conducted.
Butyrate has been demonstrated to modulate histone confor-
mation via the inhibition of histone deacetylases (HDACs), and
exerts several antitumor effects, including cell cycle inhibition,
the stimulation of cell differentiation, and the induction of
apoptosis. Several studies performed that butyrate traditionally
induces expression of speciﬁc gene expression through acting
as a potent differentiating agent in intestinal cells more than
just inhibition of multiple HDACs activities. Butyrate treatment
caused a strong interaction between CDX1 and C/EBPa in this
study. Some protein kinases can be activated by butyrate and
act to phosphorylate CDX1 and/or C/EBPa, this resulting in
favoring a physical interaction of both transcription factors.
Butyrate provides regulatory effects on the colonic Na1/H1 ex-
change promoter depended on the activity of Ser/Thr kinases,
in particular, protein kinase A [20]. We speculate that speciﬁc
kinase, including protein kinase A-dependent phosphorylation
may be the critical signal-transduction event in the hierarchyof occurrences that leads to butyrate stimulation of gene
transcription.
C/EBPa is a member of the bZIP family of transcription factors,
is expressed in many tissues, and is involved in the regulation of a
variety of biological processes, including tissue-speciﬁc metabolic
gene transcription, signal transduction, and the terminal differen-
tiation of a number of tissues, particularly adipose tissue, liver,
and intestinal tissues. C/EBPa is expressed along the crypt-to-villus
and duodenal-to-colonic axes, and performs an essential function
as a potential mediator of growth arrest and terminal differentia-
tion in the gut epithelium. In this study, C/EBPa is capable of
enhancing CDX1-mediated transactivation of the PPARc gene via
direct protein interaction depending on the combination of a vari-
ety of cellular signals, and contributes to the stimulation of buty-
rate-induced differentiation. Interestingly, the Cdx-1 activation of
the intestinal ALP gene was inhibited by Cdx-2, which lacked a
self-contained activation function, which is consistent with the
possibility that Cdx-1 and Cdx-2 may interact differentially with
accessory factors.
These studies imply that an understanding of the mechanisms
by which PPARc expression is regulated by CDX1 will provide us
with a greater insight into the maintenance of balance between
proliferation and differentiation in the normal intestine epithe-
lium, and alterations of these pathways may contribute to the pro-
cess of intestinal tumorigenesis.
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